Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Phase III Chemotherapy with ADR plus CACP for Genitourinary Carcinoma and Cancer of the Cervix and Ovary

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase III Treatment Closed no age specified UMCC-7606

Objectives

I.  Assess the clinical efficacy of adriamycin plus cis-platinum in patients 
with cancer of testicle, bladder, prostate, ureter, renal pelvis, cervix, or 
ovary.
II.  Evaluate the effectiveness of hydration, mannitol, and furosemide in 
ameliorating the renal toxicity of cis-platinum.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with biopsy proven carcinoma 
of the testicle, bladder, prostate, ureter, renal pelvis, cervix, or ovary who 
have not previously received adriamycin or cis-platinum.  Patients may not 
have a history of congestive heart failure or severe hypertension.  Patients 
must have measurable disease.

Expected Enrollment

Protocol closed April 1984.

Outline

Nonrandomized study.
2-Drug Combination Chemotherapy.  Adriamycin, ADR, NSC-123127; cis-Platinum, 
CACP, NSC-119875.

Trial Contact Information

Trial Lead Organizations

Greenebaum Cancer Center at University of Maryland Medical Center

Joseph Aisner, MD, Protocol chair
Ph: 732-235-7401
Email: aisnerjo@umdnj.edu

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.